RxDoctor Payments Data

John Fell, DO

Family Medicine · Pryor, OKNPI 1629091640

Payments from drug & device makers

$3,647in general payments, 2019–2025

Across 242 payments — averaging $15.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$748
  • Astellas Pharma US Inc$673
  • AbbVie$384
  • AstraZeneca$309
  • Sanofi-aventis U.S. LLC$267
  • Amgen$202
  • plus $1K from 21 others

What the payments were for

  • Food & beverage$3,34892%
  • Education$2998%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$3,647 in reported general payments places this provider in the 80th percentile of 1,730 family medicine providers in Oklahoma.

See all family medicine providers in Oklahoma

Medicare billing

Part B allowed, 2024
$51,719
Medicare patients
216
Services billed
912

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide74$96,045
EliquisApixaban29$31,291
Trelegy ElliptaFluticasone/Umeclidin/Vilanter38$29,271
JardianceEmpagliflozin25$27,109
OzempicSemaglutide25$25,755
LinzessLinaclotide18$20,936
FarxigaDapagliflozin Propanediol19$17,225
VraylarCariprazine Hcl11$14,961
TrulicityDulaglutide15$14,225
MyrbetriqMirabegron11$13,403
BrilintaTicagrelor12$5,067
ElmironPentosan Polysulfate Sodium12$4,156
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine87$3,642
Humalog Kwikpen U-100Insulin Lispro12$3,091
Dexlansoprazole DrDexlansoprazole12$2,932

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$150$110,27189 claims
AbbVieLinzess, Vraylar$384$35,89729 claims
PfizerEliquis$134$31,29129 claims
GSKTrelegy Ellipta$133$29,27138 claims
Boehringer IngelheimJardiance$57$27,10925 claims
Novo NordiskOzempic$748$25,75525 claims
AstraZenecaFarxiga, Brilinta$309$22,29231 claims
Astellas Pharma US IncMyrbetriq$673$13,40311 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,730 family medicine providers in Oklahoma.

Other family medicine in Pryor

See the full list for Oklahoma

Where these figures come from

Is this you, or does something look wrong? →